Episódio 230: 7 ARMADILHAS NA DOENÇA DE REFLUXO GASTROE

Rapha, Leticia e Lucca discutem 7 armadilhas na doença do refluxo gastroesofageana (DRGE)!
🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨
🔴 Junte-se aos mais de 2.000 assinantes. Assine o Guia, ganhe tempo e atualize-se sem esforço.
Deixe seu Like e siga o TdC nas outras redes sociais:
🩺 Twitter: / tadeclinicagem
🩺 Instagram: @Tadeclinicagem
🩺 Facebook: / ta-de-clinicagem
🩺 TikTok: www.tiktok.com...
Aprenda Clínica Médica de uma maneira didática, divertida e baseada em evidências!
Compartilhe o TdC com seus amigos!
Referências:
1. Fass, Ronnie. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 387,13 (2022): 1207-1216.
2. Parmar, Malvinder S. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 388,9 (2023): 863.
3. Jenkins, Danny, and Ines Modolell. “Proton pump inhibitors.” BMJ (Clinical research ed.) vol. 383 e070752. 13 Nov. 2023.
4. Katzka, David A, and Peter J Kahrilas. “Advances in the diagnosis and management of gastroesophageal reflux disease.” BMJ (Clinical research ed.) vol. 371 m3786. 23 Nov. 2020,
5. Barr J, Gulrajani NB, Hurst A, Pappas TN. Bottoms Up: A History of Rectal Nutrition From 1870 to 1920. Ann Surg Open. 2021;2(1):e039. Published 2021 Feb 10.
6.Fass, R et al. “Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.” Alimentary pharmacology & therapeutics vol. 29,12 (2009): 1261-72.
7. Lee, R. D., et al. "Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor-evidence for dosing flexibility." Alimentary pharmacology & therapeutics 29.8 (2009): 824-833.
8.Metz, D C et al. “Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.” Alimentary pharmacology & therapeutics vol. 29,7 (2009): 742-54.
9. Ip, Stanley, et al. Comparative Effectiveness of Management Strategies For Gastroesophageal Reflux Disease. Agency for Healthcare Research and Quality (US), December 2005.
10. Zhuang, Qianjun, et al. "Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis." Official journal of the American College of Gastroenterology| ACG (2022): 10-14309.
11. www.accessdata...
12. Iwakiri, Katsuhiko, et al. "Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021." Journal of gastroenterology 57.4 (2022): 267-285.
13. Graham, David Y., and Aylin Tansel. "Interchangeable use of proton pump inhibitors based on relative potency." Clinical Gastroenterology and Hepatology 16.6 (2018): 800-808.
14. Hatlebakk, J G et al. “Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.” Alimentary pharmacology & therapeutics vol. 12,12 (1998): 1235-40.
15. Chen, Joan W., et al. "AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: expert review." Clinical Gastroenterology and Hepatology (2023).
16. Gyawali, C. Prakash, et al. "Updates to the modern diagnosis of GERD: Lyon consensus 2.0." Gut 73.2 (2024): 361-371.
17. Katz, Philip O., et al. "ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease." Official journal of the American College of Gastroenterology| ACG 117.1 (2022): 27-56.
18. Hicks, Douglas M., et al. "The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers." Journal of Voice 16.4 (2002): 564-579.
19. Blondeau, Kathleen, et al. "Improved diagnosis of gastro‐oesophageal reflux in patients with unexplained chronic cough." Alimentary pharmacology & therapeutics 25.6 (2007): 723-732.